No retraction, correction or concern found when last checked on Oct 30, 2026.
Evidence for antibody as a protective correlate for COVID-19 vaccines
Kristen A. Earle, Donna M. Ambrosino, Andrew Fiore-Gartland and 5 more
Vaccine · 2021 · CC BY
doi:10.1016/j.vaccine.2021.05.063
Abstract
A correlate of protection (CoP) is urgently needed to expedite development of additional COVID-19 vaccines to meet unprecedented global demand. To assess whether antibody titers may reasonably predict efficacy and serve as the basis of a CoP, we evaluated the relationship between efficacy and in vitro neutralizing and binding antibodies of 7 vaccines for which sufficient data have been generated. Once calibrated to titers of human convalescent sera reported in each study, a robust correlation was seen between neutralizing titer and efficacy (ρ = 0.79) and binding antibody titer and efficacy (ρ = 0.93), despite geographically diverse study populations subject to different forces of infection and circulating variants, and use of different endpoints, assays, convalescent sera panels and manufacturing platforms. Together with evidence from natural history studies and animal models, these results support the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.
References 16
- 1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 6.
- 7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 13.
- 14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
Cited by papers we hold 21
- SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease · 2023No notice
- Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis · 2023No notice
- Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection · 2023No notice
- Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination · 2022No notice
- Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity · 2022Not checked
- SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year · 2022Not checked
- Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons · 2022No notice
- Extended interval BNT162b2 vaccination enhances peak antibody generation · 2022No notice
- COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection · 2022No notice
- Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies · 2022No notice
- SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway · 2022Corrected
- Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition · 2022No notice
- SARS-CoV-2 Variants, Vaccines, and Host Immunity · 2022No notice
- SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape · 2022No notice
- Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization · 2021No notice
- Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines · 2021Not checked
- Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine · 2021No notice
- Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer · 2021No notice
- Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers · 2021No notice
- Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 · 2021No notice
and 1 more
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.